Cargando…

Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT

Detalles Bibliográficos
Autores principales:	Baik, Deborah, Atreya, Raja, Bouhnik, Yoram, Casey, Daniel, Jang, Minyoung, Yoon, SangWook, Kwon, Taek S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212299/ http://dx.doi.org/10.1016/S0016-5085(22)61588-9

Ejemplares similares

Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment
por: Bouhnik, Yoram, et al.
Publicado: (2022)

Sa1055: PERCEPTIONS OF ACCESSING CARE AMONG IBD PATIENTS DURING THE COVID-19 PANDEMIC
por: Shaffer, Seth R., et al.
Publicado: (2022)

Mo1088: DIFFERENCES BETWEEN FUNCTIONAL CONSTIIPATION AND CONSTIPATION-PREDOMNANT IRRITABLE BOWEL SYNDROME WITH FOCUS PERFERCTIONISM BY STATISTICAL FACTOR ANALYSIS
por: Yamamoto, Sayuri, et al.
Publicado: (2022)

Mo1423: PATIENT PERSPECTIVES ON REMOTE HYPNOTHERAPY FOR IRRITABLE BOWEL SYNDROME DURING THE COVID-19 PANDEMIC: THE 'NEW NORM’ OR JUST A TEMPORARY SOLUTION?
por: Noble, Hithin, et al.
Publicado: (2022)

Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY
por: Li, Dalin, et al.
Publicado: (2022)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Mo1021: THE EFFECT OF HIDDEN CELIAC DISEASE ON COVID-19 IN THE COMMUNITY
por: Choung, Rok Seon, et al.
Publicado: (2022)

Mo1087: MALADAPTIVE BEHAVIORS IN PERSONS WITH IBD DURING THE COVID-19 PANDEMIC
por: Shaffer, Seth R., et al.
Publicado: (2022)

Mo1000: DISPARITIES IN HEALTHCARE UTILIZATION BEFORE, DURING, AND AFTER THE COVID-19 PANDEMIC LOCKDOWN
por: Sanaka, Harsha, et al.
Publicado: (2022)

Mo1074: FELLOW EXPERIENCES WITH ENDOSCOPY SIMULATION BEFORE AND DURING THE COVID-19 PANDEMIC: AN INTERNATIONAL SURVEY
por: Lee, Briton, et al.
Publicado: (2022)

Mo1358: IMPACT OF SARS-COV-2 INFECTION ON RECIPIENTS OF LIVER TRANSPLANT. REPORT OF A MEXICAN COHORT.
por: Azamar-Llamas, Daniel, et al.
Publicado: (2022)

Mo1020: GUT MICROBIOME CHANGES ASSOCIATED WITH HIGHER AND LONGER-LASTING ANTIBODY TITERS FOLLOWING COVID-19 VACCINATION
por: Venzon, Mericien M., et al.
Publicado: (2022)

Mo1623: FOODS OR FADS? OUTCOMES OF KETOGENIC, PLANT-BASED, AND INTERMITTENT FASTING DIETS: A SYSTEMATIC REVIEW AND METAANALYSIS
por: Srinivasan, Sachin, et al.
Publicado: (2022)

Mo1054: DIAGNOSTIC STRATEGIES FOR HELICOBACTER PYLORI IN PATIENTS WITH BLEEDING PEPTIC ULCERS UNDERGOING ENDOSCOPY: A COST-EFFECTIVENESS ANALYSIS
por: Artin, Michael G., et al.
Publicado: (2022)

Mo1086: MENTAL HEALTH IN IBD DURING THE COVID-19 PANDEMIC: ACCESS TO MENTAL HEALTH CARE AND EXPOSURE TO PANDEMIC NEWS
por: Shaffer, Seth R., et al.
Publicado: (2022)

Mo1019: THE IMPACT OF IBS ON SELF-REPORTED PHYSICAL AND MENTAL HEALTH DURING THE COVID PANDEMIC – A NORWEGIAN TWIN STUDY
por: Kutschke, Julia, et al.
Publicado: (2022)

Mo1621: DISTINCT PHENOTYPES OF MULTI-ORGAN ABNORMALITIES IN LONG COVID AND TYPE 2 DIABETES IDENTIFIED BY MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING
por: Eichert, Nicole, et al.
Publicado: (2022)

Mo1622: EFFICACY OF GLP-1 ANALOGS AND AGONISTS ON PROPORTION OF WEIGHT LOSS IN OVERWEIGHT OR OBESE DIABETICS AND NONDIABETICS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Vosoughi, Kia, et al.
Publicado: (2022)

Mo1620: ECTOPIC FAT DEPOSITION IN THE LIVER AND PANCREAS AND THE PRESENCE OF EXCESS VISCERAL ADIPOSE TISSUE SIGNIFICANTLY INCREASE HOSPITALISATION RISK FOLLOWING COVID-19.
por: Waddell, Tom H., et al.
Publicado: (2022)

Fr501 BIOLOGICS AND COVID-19 OUTCOMES IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Weissman, Simcha, et al.
Publicado: (2021)

EP1270: SEROCONVERSION IN INFLAMMATORY BOWEL DISEASE PATIENTS AFTER COVID-19 VACCINATION
por: Horvath, Miklos, et al.
Publicado: (2022)

Tu1544: HUMORAL AND T CELL RESPONSES TO COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

Fr496 THE EFFECTS OF COMORBIDITIES ON COVID-19 OUTCOMES AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Parekh, Rajen, et al.
Publicado: (2021)

Fr500 COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS
por: Tripathi, Kartikeya, et al.
Publicado: (2021)

Fr502 INFLAMMATORY BOWEL DISEASE AND COVID-19: A LARGE INTEGRATED HEALTHCARE EXPERIENCE
por: Tashjian, Vartan C., et al.
Publicado: (2021)

Su1495: COVID-19 VACCINE HESITANCY REMAINS HIGH IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Kwon, Hyuk Joon, et al.
Publicado: (2022)

Su1491: ATTITUDES AND PREDICTORS OF COVID-19 VACCINE UPTAKE IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

Su1498: SAFETY OF COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE PATIENTS ON BIOLOGIC THERAPY
por: Garrido, Isabel, et al.
Publicado: (2022)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

Sa571 EVALUATION OF MENTAL STATE AND CLINICAL SYMPTOMS OF CORONAVIRUS PANDEMIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Tani, Mizuki, et al.
Publicado: (2021)

Sa1064: IMPACT OF COVID-19 PANDEMIC ON PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A LOCAL REPORT
por: Tsipotis, Evangelos, et al.
Publicado: (2022)

Su1487: IMPACT OF INFLAMMATORY BOWEL DISEASE THERAPIES ON DURABILITY OF HUMORAL RESPONSE TO SARS COV-2 VACCINATION
por: Charilaou, Paris, et al.
Publicado: (2022)

Tu1547: COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Meybodi, Mohamad Aghaie, et al.
Publicado: (2022)

Sa1053: OUTCOMES OF HOSPITALIZED COVID-19 PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONAL DATABASE STUDY
por: Melquist, Stephanie J., et al.
Publicado: (2022)

Fr509 COVID-19 OUTCOMES AMONG RACIAL AND ETHNIC MINORITY INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASES IN THE UNITED STATES
por: Agrawal, Manasi, et al.
Publicado: (2021)

Fr103 STRATIFYING THE IMPACT OF COVID-19 PANDEMIC ON THE EMOTIONAL AND PHYSICAL WELL-BEING OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
por: El-Dallal, Mohammed, et al.
Publicado: (2021)

Sa502 THE FIRST AND SECOND WAVE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A TEMPORAL TREND ANALYSIS
por: Kaplan, Gilaad, et al.
Publicado: (2021)

Su1489: HUMORAL IMMUNOGENICITY OF THREE SARS-COV-2 MRNA VACCINE DOSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Schell, Trevor, et al.
Publicado: (2022)

Fr498 NEW GASTROINTESTINAL SYMPTOMS ARE COMMON IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH COVID-19: DATA FROM AN INTERNATIONAL REGISTRY
por: Ungaro, Ryan C., et al.
Publicado: (2021)

Fr497 INCIDENCE AND OUTCOMES OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Khan, Shahab R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pvl43mlbimqn2tgffo7vcmful9